Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab pharmacokinetics in primary glomerular kidney diseases
2020-000484-23Phase 4Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in chronic kidney disease (CKD), membranous glomerulonephritis (MGN), nephrosis and 2 more, sponsored by Vall d'Hebron Research Institute. Primary endpoints: Serum rituximab concentration, Rituximab half-life and 3 more. Started Sep 2024; status: active.
02
Drugs
rituximab
03
Conditions
chronic kidney disease (CKD)membranous glomerulonephritis (MGN)nephrosisvasculitisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2020-000484-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000484-23.